



IDT Biologika to concentrate on human vaccines and pharmaceuticals

Divestment of animal health business unit enables focus on global growth market

Dessau, Germany, June 5th, 2019

IDT Biologika, an integrated global contract manufacturer of vaccines and biopharmaceuticals, is set to focus on the production of human vaccines and medicines going forward by divesting its portfolio of veterinary pharmaceuticals and related R&D activities to the French veterinary health group [Ceva Santé Animale](#) – pending approval by Germany's Federal Cartel Office.

Business in contract manufacturing and development of human medicines has seen dynamic growth over the past few years for the long-standing, Dessau-based company, most recently contributing as much as two thirds of total turnover. In this market, IDT acts as a partner to mostly international pharmaceutical companies, with demand for such services growing comfortably in the two-digit range. IDT's goal is to establish itself as one of the global leaders in this field, according to CEO Jürgen Betzing.

The company is currently adapting its organization, processes and structures to the new strategic direction. As a result of the ongoing restructuring, management estimates that about 1,600 of the current around 1,900 jobs at the Dessau site can be secured, with some of these staff being employed by the new owner of the animal health business going forward. The company expects to be able to achieve the necessary downsizing largely without any forced redundancies.

Comments Jürgen Betzing, CEO: "IDT is an innovative biotech company with a long tradition here in the region. Drawing on modern technology and outstanding skills, we support our customers in developing and manufacturing vaccines and biological medicines that help fight diseases all over the world. Our strategic repositioning will

enable us to fully concentrate on a very promising high-growth market in which we're committed to gaining a leading global position."

IDT, whose roots are in animal health, has built a strong reputation as a contract manufacturing organization (CMO) for human medicines for the pharmaceutical and biopharmaceutical industry recently. This is reflected, for example, in its having won both the [CMO Leadership Award](#) as a leading global supplier in March this year and the [ViE Award](#) (Vaccine Industry Excellence) in the Contract Manufacturing Organization category in May.



CEO of the IDT Biologika GmbH: [Dr. Jürgen Betzing](#)

About IDT Biologika

IDT Biologika is an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards, for its own animal health products and under contract.

Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. IDT's Animal Health business is marketed internationally from its offices in Denmark, the Netherlands, France, Spain, Poland and China. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland. Autogenous vaccines are produced by the recently acquired IDT subsidiary in the United Kingdom, Ridgeway Biologicals.

IDT Biologika is a member of the Klocke Group, which specializes in contract production and packaging of medications, vaccines and cosmetic products. As a traditional family-owned company, the Klocke Group employs a workforce of more than 2,400 people at eight production sites and sales offices around the world. For more information, visit www.idt-biologika.com.

Contact

Christian Herschel
External Corporate Communications
Tel +49 34901 885 4293
Pressestelle@idt-biologika.de

IDT Biologika GmbH
Am Pharmapark, 06861 Dessau-Roßlau, Germany